Sanofi has decided to discontinue the Phase 1 clinical trial and development of SAR448272, an oral STAT6 degrader developed in collaboration with Nurix Therapeutics. As a result, Nurix will no longer receive milestone payments or royalties related to this program but remains eligible for payments from other partnered programs. Despite this setback, Nurix maintains a strong financial position with $1.1 billion in cash and ongoing clinical programs, including a Phase 3 trial for a BTK degrader and Phase 1b studies for other cancer and autoimmune treatments. The company continues to advance its pipeline and collaborations with Roche, Gilead, and Pfizer.
As of Nov 04, 2026 04:11 WIB, Sanofi (SNY) shares are trading at USD 45.40, up 2.39% on Pluang, with a market cap of $107.77 billion. Meanwhile, Gilead Sciences (GILD), a collaborator mentioned in the news, is priced at USD 167.05, down 1.93% as of the same time. Sanofi's dividend yield stands at 5.31%, reflecting steady income potential for investors on the platform.
Regeneron Pharmaceuticals' stock surged 12% after reporting a 36% revenue increase to $5.1 billion in Q3 2026, beating analyst expectations. The boost was largely due to its partnership with Sanofi, with Dupixent sales rising 35%, and record sales of...
Regeneron reported a 36% revenue increase to $5.1 billion in Q3 2026, with record sales for Dupixent, EYLEA HD, and Libtayo. GAAP EPS rose 35% to $18.45, and non-GAAP EPS jumped 70% to $20.07. The company expanded its collaboration with Sanofi, secur...
